Wrist & Hand Repetitive Use Injuries | NYU Langone Health
NYU Langone orthopedists diagnose and treat many types of overuse injuries to the hand and wrist.
WUH: COG# AGCT1531: A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients with Germ Cell Tumors
?Despite recent improvements in outcome for children with newly diagnosed high-risk neuroblastoma, cure rates remain unsatisfactory. Further, these gains have been the result of interventions during the Consolidation (tandem autologous stem cell transplant) and Post-Consolidation (dinutuximab immunotherapy) phases of treatment, while rates of disease control during Induction have not improved in recent COG trials. The current phase 3 trial seeks to improve the event-free survival (EFS) for children with high-risk neuroblastoma through early integration of promising novel targeted therapies: targeted radiopharmaceutical therapy with 131I-MIBG or the ALK inhibitor, crizotinib. After enrollment, patients will receive one cycle of Induction chemotherapy. Subsequent therapy will be based upon MIBG avidity and ALK status. Patients with MIBG-avid, ALK wild type (or ALK unknown) disease will be randomized to one of three arms: A) current COG recommended high-risk therapy including four more cycles of Induction chemotherapy and surgical resection of the primary tumor, Consolidation with tandem transplant and focal external beam radiation, and dinutuximab immunotherapy with isotretinoin; B) current COG recommended high-risk therapy with the addition of a block of 131I-MIBG after the third Induction cycle; or C) current COG recommended high-risk therapy with the addition of a block of 131I-MIBG after the third Induction cycle and substitution of busulfan / melphalan (BuMel) single autologous stem cell transplant in place of tandem transplant. Patients with MIBG non-avid, ALK wild type (or ALK unknown) disease will be non-randomly assigned to receive current COG recommended high-risk therapy without the addition of 131I-MIBG. Patients with ALK aberrant tumors (ALK tyrosine kinase mutation or ALK amplification) will be non-randomly assigned to receive crizotinib added to current COG recommended high-risk therapy. The primary endpoint is EFS and 774 eligible and evaluable patients are anticipated to enroll over approximately 5 years. Key secondary endpoints are toxicity, end-Induction response, and overall survival. Late effects of therapy including targeted therapies will be compared with late effects of current COG recommended treatment. Embedded correlative studies seek to understand predictors of benefit and resistance to 131I-MIBG and crizotinib.
X-Ray Imaging | NYU Langone Health
NYU Langone offers bone, chest, abdominal, and dental X-rays.
Young Lung Cancer Program | NYU Langone Health
Experts at the Young Lung Cancer Program, part of NYU Langone’s Lung Cancer Center, offer personalized care for younger people with lung cancer.
Young Onset Parkinson s disease Subtypes and Pathogenic Mechanisms
Young Onset Parkinson’s disease refers to a -group of patients in which the disease starts earlier in life (before the age of 50 years) and has a profound impact on most of patient’s life and on important productive years. Our current knowledge regarding the pathogenic mechanisms of YOPD is lacking, and understanding these are crucial for the successful design of therapeutic strategies and stratifying patients for clinical trials. The proposed research is relevant to public health because it aims to clarify the contribution of recognized important pathogenic mechanisms of Parkinson’s disease (genetics, inflammation, and alpha-synuclein accumulation) in patient with Young onset Parkinson’s disease to help patient stratification for clinical counseling and clinical trials.With the present project we propose to study a cohort of subjects with YOPD (n = 150) compared to n=50 LOPD and n=50 CTRLs. For each enrolled subject we will collect clinical data and biospecimens including blood specimen, skin punch biopsy. CSF will be collected from a sub-cohort of subjects (n = 20 YOPD, n = 20 LOPD, n = 20 CTRLs).
Your Cancer Care Team | NYU Langone Health
At Perlmutter Cancer Center, your cancer care team works together to provide individualized diagnostic testing and treatment.
Your Child’s Care Team | NYU Langone Health
Meet the members of the care team at Hassenfeld Children’s Hospital at NYU Langone.
Your Child's ECMO Treatment | NYU Langone Health
At Hassenfeld Children’s Hospital at NYU Langone, we provide support while your child is receiving extracorporeal membrane oxygenation (ECMO).
Your Child’s Visit | NYU Langone Health
We help you prepare for your child’s visit to Hassenfeld Children’s Hospital at NYU Langone.
Your Emergency Care Visit | NYU Langone Health
NYU Langone offers information about what to expect during your emergency care visit in Manhattan, Brooklyn, or Long Island.